| Factor Information | |
|---|---|
| Data ID | 269 |
| Factor | SpO2 |
| Description | N/A |
| Biomarker | NA |
| Classification | E11 (physiological factor - physical sign) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | infants with CHD |
| p Value | <0.001 |
| Conclusion | The oxygen saturation was significantly lower in the cyanotic group compared to the acyanotic group |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 435 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | HRV/HLHS/SV/DILV/TAPVR/TOF/TOF, CAVC/CAVC/D-TGA, IVS/EA, w-PA/PS/Supracardiac TAPVR/Infracardiac TAPVR/Subaortic VSD w-PS/VSD/TA/TA/AS, CoA/CoA/PDA/VSD, HAA/DORV, PS |
| Reference | |
|---|---|
| PMID | 30430186 |
| Year | 2019 |
| Title | A Novel Brain Injury Biomarker Correlates with Cyanosis in Infants with Congenital Heart Disease. |
| Sample | ||
|---|---|---|
| Population | infant | |
| Source | blood | |
| Region | America, New York | |
| Method | cytokine analysis | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Cyanotic CHD patients(Treatment) | Cyanotic CHD patients(Control) |
| Number | 22 | 28 |
| Age | 72±98 days | 102±78 days |
| Gender (Male: Female) | 10:12 | 13:15 |
| Marker Level | 78±18% | 98±2% |
